Projects funded by the NCN
The combination of radiotherapy with imiquimod and sunitinib as a new therapeutic strategy overcoming some of the tumor microenvironment-mediated radio-resistance mechanisms.
2018/31/D/NZ5/01754
Keywords:
radiotherapy imiquimod sunitinib tumor microenvironment radio-resistance immunomodulation anti-angiogenic therapy
Descriptors:
- NZ5_7: Human disease treatment
- NZ4_12: Other related subjects
- NZ6_1: Adaptive and innate immunity
Panel:
NZ5 - Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)
Host institution :
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Oddział w Gliwicach
woj. śląskie
Principal investigator (from the host institution):
Number of co-investigators in the project: 5
Call: SONATA 14 - announced on 2018-09-14
Amount awarded: 668 800 PLN
Project start date (Y-m-d): 2019-06-28
Project end date (Y-m-d): 2025-06-27
Project duration:: 36 months (the same as in the proposal)
Project status: Pending project
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (1)
- Brachytherapy in a Single Dose of 10Gy as an in situ" VaccinationAuthors:Magdalena Jarosz-Biej, Ryszard Smolarczyk, Tomasz Cichoń, Alina Drzyzga, Justyna Czapla, Zbigniew Urbaś, Ewelina Pilny, Sybilla Matuszczak and Piotr WojcieszekAcademic press:International Journal of Molecular Sciences (rok: 2020, tom: 21, strony: 4585), Wydawca: MDPIStatus:PublishedDOI:10.3390/ijms21134585 - link to the publication